<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>175(3)</volume><submitter>de Groot AF</submitter><funding>Amgen</funding><funding>Dutch Cancer Society</funding><funding>Sanofi</funding><funding>Novartis</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Tumor-infiltrating lymphocytes (TILs) are associated with pathological complete response (pCR) and survival after neoadjuvant chemotherapy (NAC) in patients with early breast cancer. We investigated the prognostic and predictive role of TILs, macrophages, and HLA class 1 expression after NAC with or without the potentially immune modulating compound zoledronic acid (ZA).&lt;h4>Methods&lt;/h4>Baseline tumor biopsies from 196 patients in the NEOZOTAC trial were analyzed for CD8 (cytotoxic T-cells), FoxP3 (regulatory T-cells), CD68 (macrophages), and HLA class I (HCA2/HC10) expression by immunohistochemistry and subsequently related to pCR and disease-free survival (DFS).&lt;h4>Results&lt;/h4>A strong intratumoral CD8+ infiltration or expression of HLA class 1 by cancer cells was associat</pubmed_abstract><journal>Breast cancer research and treatment</journal><pagination>605-615</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6534526</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.</pubmed_title><pmcid>PMC6534526</pmcid><pubmed_authors>Putter H</pubmed_authors><pubmed_authors>Smit VTHBM</pubmed_authors><pubmed_authors>Engels CC</pubmed_authors><pubmed_authors>de Groot AF</pubmed_authors><pubmed_authors>Blok EJ</pubmed_authors><pubmed_authors>van de Velde CJH</pubmed_authors><pubmed_authors>Meershoek-Klein Kranenbarg E</pubmed_authors><pubmed_authors>van der Burg SH</pubmed_authors><pubmed_authors>Charehbili A</pubmed_authors><pubmed_authors>Dekker-Ensink NG</pubmed_authors><pubmed_authors>Kuppen PJK</pubmed_authors><pubmed_authors>Liefers GJ</pubmed_authors><pubmed_authors>Nortier JWR</pubmed_authors><pubmed_authors>Kroep JR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.</name><description>&lt;h4>Purpose&lt;/h4>Tumor-infiltrating lymphocytes (TILs) are associated with pathological complete response (pCR) and survival after neoadjuvant chemotherapy (NAC) in patients with early breast cancer. We investigated the prognostic and predictive role of TILs, macrophages, and HLA class 1 expression after NAC with or without the potentially immune modulating compound zoledronic acid (ZA).&lt;h4>Methods&lt;/h4>Baseline tumor biopsies from 196 patients in the NEOZOTAC trial were analyzed for CD8 (cytotoxic T-cells), FoxP3 (regulatory T-cells), CD68 (macrophages), and HLA class I (HCA2/HC10) expression by immunohistochemistry and subsequently related to pCR and disease-free survival (DFS).&lt;h4>Results&lt;/h4>A strong intratumoral CD8+ infiltration or expression of HLA class 1 by cancer cells was associat</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jun</publication><modification>2025-05-18T11:02:39.795Z</modification><creation>2025-05-18T11:02:39.795Z</creation></dates><accession>S-EPMC6534526</accession><cross_references><pubmed>30868392</pubmed><doi>10.1007/s10549-019-05195-y</doi></cross_references></HashMap>